Article
PCSK9 inhibitors: the next frontier in low-density lipoprotein lowering.
Metabolic syndrome and related disorders - 1 Apr 2015
Jialal Ishwarlal, Patel Shailendra B
Abstract excerpt
The discovery and elucidation of the role of the low-density lipoprotein receptor (LDL-R) in familial hypercholesterolemia (FH) ushered in the statin group of drugs. These drugs, in addition to lowering low-density lipoprotein cholesterol (LDL-C), result in a significant reduction in cardiovascular events (CVE) and mortality. Recently, a gain-of-function mutation in another protein, proprotein convertase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.